Markets:

Overview

News

Currencies

International

Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

23.94 -0.93 (-3.74%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Apellis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with Geographic Atrophy (GA)

November 04, 2023

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

APELLIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Apellis Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

November 02, 2023

From Bragar Eagel & Squire

Via GlobeNewswire

21 Analysts Have This to Say About Apellis Pharmaceuticals ↗

November 02, 2023

Via Benzinga

Apellis Pharmaceuticals Reports Third Quarter 2023 Financial Results

November 01, 2023

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Analyst Ratings for Apellis Pharmaceuticals ↗

October 06, 2023

Via Benzinga

Why Apellis Pharmaceuticals Stock Popped Today ↗

October 05, 2023

Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) shares are trading higher Thursday after the company reported preliminary U.S.

Via Benzinga

Inside Cathie Wood’s Portfolio: 3 Stocks She Is Betting Millions On ↗

November 01, 2023

Are you looking to invest in disrupting stocks like Cathie Woods? Here are three stocks Cathie Wood is betting millions on.

Via InvestorPlace

10 Health Care Stocks Whale Activity In Today's Session ↗

October 31, 2023

Via Benzinga

Apellis Pharmaceuticals Stock Improves With An RS Ratings Over 90 ↗

October 31, 2023

Apellis Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Via Investor's Business Daily

Apellis Pharmaceuticals to Host Conference Call on November 1, 2023, to Discuss Third Quarter 2023 Financial Results

October 25, 2023

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Apellis Pharmaceuticals Stock Shows Rising Relative Strength ↗

October 24, 2023

A Relative Strength Rating upgrade for Apellis Pharmaceuticals shows improving technical performance. Will it continue?

Via Investor's Business Daily

The Lancet Publishes 24-Month Results from Phase 3 Studies of SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy (GA)

October 20, 2023

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

10 Health Care Stocks Whale Activity In Today's Session ↗

October 18, 2023

Via Benzinga

Apellis to Present Positive Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G at Kidney Week

October 17, 2023

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Stocks Mixed Amid Earnings, Consumer Sentiment Data ↗

October 13, 2023

Stocks are mixed this afternoon, as investors unpack earnings reports from several bank giants as well as economic data.

Via Talk Markets

JPMorgan, Wells Fargo, Citigroup And Other Big Stocks Moving Higher On Friday ↗

October 13, 2023

U.S. stocks traded mostly higher, with the Dow Jones gaining more than 100 points on Friday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

Why Pioneer Natural Resources Shares Are Bouncing By Around 12%; Here Are 20 Stocks Moving Premarket ↗

October 06, 2023

Gainers Vaccinex, Inc. (NASDAQ: VCNX) shares rose 40.2% to $1.15 in pre-market trading as two large insider buys were reported after the close on Thursday.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2023 ↗

October 06, 2023

Via Benzinga

Constellation Brands To Rally Over 20%? Here Are 10 Other Analyst Forecasts For Friday ↗

October 06, 2023

HSBC raised the price target for Constellation Brands, Inc. (NYSE: STZ) from $280 to $290. HSBC analyst Carlos Laboy maintained a Buy rating. Constellation shares fell 3.2% to close at $241.33 on...

Via Benzinga

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 05, 2023

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Apellis Announces Preliminary U.S. Net Revenues of Approximately $74 Million for SYFOVRE® (pegcetacoplan injection) in the Third Quarter of 2023

October 05, 2023

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

APLS DEADLINE TODAY: ROSEN, A LEADING NATIONAL FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 2 Deadline in Securities Class Action - APLS

October 02, 2023

WHY: NEW YORK, NY - (NewMediaWire) - October 2, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) between...

Via TheNewswire.com

Topics Lawsuit

APLS DEADLINE TODAY: ROSEN, A LEADING NATIONAL FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 2 Deadline in Securities Class Action - APLS

October 02, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

NASDAQ:APLS Shareholder Alert: Deadline on October 2, 2023 Coming Up in Lawsuit Against Apellis Pharmaceuticals, Inc. ↗

October 02, 2023

San Diego, CA -- (SBWIRE) -- 10/02/2023 -- A deadline is coming up on October 2, 2023 in the lawsuit filed for certain investors of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS).

Via SBWire

Topics Lawsuit

Apellis Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-Administration

October 02, 2023

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

APLS DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors in Excess of $100K to Secure Counsel Before Important October 2 Deadline in Securities Class Action - APLS

September 30, 2023

WHY: NEW YORK, NY - (NewMediaWire) - September 29, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) between...

Via TheNewswire.com

Topics Lawsuit

APELLIS 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. - APLS

September 29, 2023

From Kahn Swick & Foti, LLC

Via Business Wire

APELLIS DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Apellis Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm

September 29, 2023

From Bragar Eagel & Squire, P.C.

Via Business Wire

September 29, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. (APLS)

September 29, 2023

From The Law Offices of Frank R. Cruz

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.